(Morrisville, N.C.) TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its next generation product of its LipiFlow® Thermal Pulsation System , a medical device that treats evaporative dry eye by liquefying and evacuating obstructions in meibomian glands located in the eyelids. The second generation product includes a more robust graphical user interface and provides the ability for physicians to treat both of a patient’s eyes simultaneously. (more…)

(Durham, N.C.) Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the German Institute for Medical Documentation and Information (DIMDI, Cologne) has revised the procedure code for the treatment of coronary bifurcations lesions, distinguishing dedicated side branch stent systems from conventional technique and providing for additional reimbursement for use of the Tryton side branch stent. (more…)

(Durham, N.C.) Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced completion of patient enrollment in the intravascular ultrasound (IVUS) cohort of the randomized, controlled Tryton IDE Study evaluating the TRYTON Side Branch Stent for the treatment of bifurcation disease. Results of the multi-national Tryton IDE Study will be submitted to the U.S. Food and Drug Administration (FDA) for approval to market the device in the United States. (more…)

(Morrisville, N.C.) TearScience®, Inc., a privately-held medical device company, today announced that it has appointed Diethart Reichardt as senior vice president of the European region including Europe, Middle East and Africa. In this role, Reichardt will be responsible for sales, marketing, operations and customer service teams based in the European region as well as a distributor network in Africa and the Middle East. Reichardt will be based in Germany. TearScience’s advanced solutions are designed to help eye care physicians treat patients suffering from evaporative dry eye disease and Meibomian Gland Dysfunction. (more…)

(Morrisville, N.C.) TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow® Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye. The clearance enables TearScience to market and sell LipiFlow® to eye care physicians in the U.S. LipiFlow® will be available immediately, but on a limited basis in the U.S. through the end of 2011. LipiFlow® removes meibomian gland obstructions by applying directed energy to a patient’s eyelid during a 12-minute in-office treatment. (more…)

(Winston-Salem, N.C.) As part of an ongoing initiative to inspire and support the next generation of innovators in the Forsyth County community, Cook Medical, the Winston-Salem Chamber of Commerce and the Chamber’s Technology Council are proud to announce the third annual Cook Medical Innovation Award. Open to organizations, companies and individuals, the award will be given to the most outstanding locally developed and novel technologies that positively affect society. The award will be recognized on November 30, 2011 at the Chamber of Commerce Annual Meeting. (more…)

(Morrisville, N.C.) TearScience, Inc., a privately-held medical device company, announced that the Toronto-based Herzig Eye Institute, one of the leading authorities in laser vision correction and advanced cataract and refractive surgery, is the first eye care centre in North America to introduce the innovative LipiFlow® evaporative dry eye disease treatment system, which has received a medical device license from Health Canada. (more…)

(Morrisville, N.C.) TearScience, Inc., a privately-held medical device company, today announced that its LipiView® Ocular Surface Interferometer has received the Medical Design Excellence Award from UBM Canon. The LipiView provides eye care physicians with a new, in-office tear film procedure for dry eye patients, which takes less than 5 minutes. (more…)

(Durham, N.C.) Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first U.S. patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease. (more…)

(Morrisville, N.C.) TearScience, Inc., a privately-held medical device company, today announced that it has received the Southeast Deal of the Year Venture Capital Transaction Award from Southeast BIO (SEBIO), a nonprofit organization that fosters the growth of the life sciences industry in the U.S. Southeastern region. TearScience was recognized for having raised $44.5 million Series C financing in May, 2010. TearScience’s C round investors included Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker BioVentures. (more…)

(Durham, N.C.) Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease. Indulis Kumsars, M.D., chief of the catheterization laboratory at Pauls Stradins Clinical University Hospital in Riga, Latvia, enrolled the first patient. (more…)

(Durham, N.C.) Sonamba, a new wellbeing monitor from pomdevices, LLC, has been awarded a finalist position at this month’s i-stage event for next-gen technologies. The event is hosted by the Consumer Electronics Association (CEA). (more…)